Cargando…

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential assessment of levels of residual disease and investigation of possible reasons for resistance, relapse or progression. Our s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cross, Nicholas C. P., Ernst, Thomas, Branford, Susan, Cayuela, Jean-Michel, Deininger, Michael, Fabarius, Alice, Kim, Dennis Dong Hwan, Machova Polakova, Katerina, Radich, Jerald P., Hehlmann, Rüdiger, Hochhaus, Andreas, Apperley, Jane F., Soverini, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624636/ https://www.ncbi.nlm.nih.gov/pubmed/37794101 http://dx.doi.org/10.1038/s41375-023-02048-y

Ejemplares similares

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
por: Hochhaus, A., et al.
Publicado: (2020)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
por: Steegmann, J L, et al.
Publicado: (2016)

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet
por: Itzykson, Raphael, et al.
Publicado: (2018)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
por: Schäfer, Vivien, et al.
Publicado: (2021)

Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet
por: van der Velden, Vincent H. J., et al.
Publicado: (2021)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2020)

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera
por: Tremblay, Douglas, et al.
Publicado: (2022)

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
por: Wille, Kai, et al.
Publicado: (2023)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
por: Bataller, Alex, et al.
Publicado: (2022)

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
por: Mrózek, Krzysztof, et al.
Publicado: (2023)

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013)

Role of Epigenetics in Chronic Myeloid Leukemia
por: Machova Polakova, Katerina, et al.
Publicado: (2013)

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
por: Hochman, Michael J., et al.
Publicado: (2023)

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response
por: Begna, K. H., et al.
Publicado: (2022)

Effects of Intermittent Fasting on Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia: An Outcome of European LeukemiaNet Project
por: Yassin, Mohamed A., et al.
Publicado: (2021)

Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia
por: Bill, Marius, et al.
Publicado: (2020)

Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022)

A three-gene expression-based risk score can refine the European LeukemiaNet AML classification
por: Wilop, Stefan, et al.
Publicado: (2016)

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
por: Sargas, Claudia, et al.
Publicado: (2023)

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group
por: Porwit, Anna, et al.
Publicado: (2022)

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing
por: Linhartova, Jana, et al.
Publicado: (2015)

Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project
por: Abdulla, Mohammad A. J., et al.
Publicado: (2021)

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
por: Tettero, Jesse M., et al.
Publicado: (2021)

Chronic Myeloid Leukemia in 2020
por: Hehlmann, Rüdiger
Publicado: (2020)

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
por: Medeiros, B C, et al.
Publicado: (2014)

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
por: Cross, N C P, et al.
Publicado: (2015)

Correction Notice: Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Publicado: (2022)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

Genomic Instability in Context of the Chromosomal Theory
por: Fabarius, Alice, et al.
Publicado: (2008)

S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Bill, Marius, et al.
Publicado: (2023)

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study
por: Stauder, Reinhard, et al.
Publicado: (2018)

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
por: Radich, Jerald P., et al.
Publicado: (2023)

From molecular interaction to acute promyelocytic leukemia: Calculating leukemogenesis and remission from endogenous molecular-cellular network
por: Yuan, Ruoshi, et al.
Publicado: (2016)

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance
por: de Swart, Louise, et al.
Publicado: (2017)

The New ELN Recommendations for Treating CML
por: Hehlmann, Rüdiger
Publicado: (2020)

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
por: Abruzzese, Elisabetta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fdslhlepgj9pg5fmsrl0gdenet